TAGRISSO: payments to doctors
Payments that named TAGRISSO as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $14.8M
- Providers
- 12,055
- Transactions
- 43,591
- Average per transaction
- $339
The per-transaction average — $339 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 12,055 providers the average total is $1,225, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| AstraZeneca | $14,164,563 | 95.9% |
| Astrazeneca UK Limited | $593,998 | 4.0% |
| Acerta Pharma LLC | $10,064 | 0.1% |
| Astrazeneca AB | $1,068 | 0.0% |